n3 PUFA and Muscle-disuse Atrophy in Older Women

• ClinicalTrials.gov Identifier: NCT03808519
• Recruitment Status: Unknown
• First Posted: January 17, 2019
• Last Update Posted: February 17, 2020
• Sponsor: McMaster University
• Information provided by (Responsible Party): Stuart Phillips, McMaster University

Study Description

Brief Summary:

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in older women undergoing 1 week of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Condition or disease	Intervention/treatment	Phase
Muscle Atrophy; Muscle Disuse Atrophy; Sarcopenia	Dietary Supplement: n3 PUFA-enriched fish oil; Dietary Supplement: Placebo	Not Applicable

Detailed Description:

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. More importantly, older adults (especially older women) that experience periods of muscle disuse are unable to recover muscle mass and strength. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. A previous study from our group demonstrated that younger women supplementing with n3 PUFA-enriched fish oil attenuated declines in skeletal muscle mass and strength during 2 weeks of immobilization. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization in older women.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Basic Science
• Official Title: Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Older Women
• Actual Study Start Date: February 18, 2019
• Actual Primary Completion Date: February 1, 2020
• Estimated Study Completion Date: August 31, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: n3 PUFA; n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)	Dietary Supplement: n3 PUFA-enriched fish oil; 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Placebo Comparator: Placebo; Organic Sunflower Oil 5000mg per day	Dietary Supplement: Placebo; Organic Sunflower Oil 5000mg per day

Outcome Measures

Primary Outcome Measures :

1. Muscle Cross-Sectional Area [ Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days) ]
   Changes in muscle cross-sectional area assessed by ultrasonography

Secondary Outcome Measures :

1. Integrated rates of muscle protein synthesis [ Time Frame: pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days) ]
   Change in muscle protein synthesis using doubly labelled water (D2O)
2. Skeletal muscle strength [ Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days) ]
   Change in skeletal muscle strength using the Biodex Dynamometer
3. Endothelial function [ Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days) ]
   Change in flow-mediated dilation
4. Vascular function [ Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days) ]
   Change in total femoral flow

Eligibility Criteria

• Ages Eligible for Study: 55 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Gender Eligibility Description: self- representation of gender identity
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Female
• Aged 55 - 75 years old
• non-smoking (for at least 2 years)
• > 5 years post-menopausal
• Body mass index (BMI) between 22 and 33 kg/m2
• Mini-Mental State Exam (MMSE) score > 20
• Acceptable medications include: Angiotensin Converting Enzyme (ACE), Beta-Blockers, Acetylsalicylic Acid, Calcium Channel blockers, Depression/Anxiety meds, Bisphosphonates (Fosamax®, Didrocal®, Actonel®, Aclasta®).

Exclusion Criteria:

• Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements.
• History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years.
• Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral n-3 PUFA supplement ingestion and/or assessment of safety and study objectives
• Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing)
• Participation in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study
• Hypersensitivity to the test product
• Excessive alcohol consumption (>21 units/week)
• Prior gastrointestinal bypass surgery
• History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy
• Personal or family history of clotting disorder or deep vein thrombosis
• Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), or any anabolic steroid

Contacts and Locations

Locations

Canada, Ontario

Exercise Metabolism Research Laboratory, McMaster Univeristy

Hamilton, Ontario, Canada, L8S 4K1

Sponsors and Collaborators

McMaster University

Investigators

• Principal Investigator: Stuart M Phillips, PhD; McMaster University

More Information

• Responsible Party: Stuart Phillips, Professor, McMaster University
• ClinicalTrials.gov Identifier: NCT03808519
• Other Study ID Numbers: HiREB 1932
• First Posted: January 17, 2019
• Last Update Posted: February 17, 2020
• Last Verified: February 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Stuart Phillips, McMaster University:

n3 PUFA

Additional relevant MeSH terms:

Muscular Disorders, Atrophic; Sarcopenia; Muscular Atrophy; Atrophy; Pathological Conditions, Anatomical; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases